Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 5/2012

Open Access 01-10-2012 | Research article

Mannose binding lectin: a biomarker of systemic lupus erythematosus disease activity

Authors: Aditya K Panda, Jyoti R Parida, Rina Tripathy, Sarit S Pattanaik, Balachandran Ravindran, Bidyut K Das

Published in: Arthritis Research & Therapy | Issue 5/2012

Login to get access

Abstract

Introduction

A role for mannose binding lectin (MBL) in autoimmune diseases has been demonstrated earlier and elevated level of MBL has been shown in systemic lupus erythematosus (SLE) patients. In the current study, we investigated MBL as a potential biomarker for disease activity in SLE.

Methods

In a case control study SLE patients (93 females) and 67 age, sex, ethnicity matched healthy controls were enrolled. Plasma MBL levels were quantified by enzyme linked immunosorbent assay (ELISA). Clinical, serological and other markers of disease activity (C3, C4 and anti-dsDNA) were measured by standard laboratory procedures.

Results

Plasma MBL levels were significantly high in SLE patients compared to healthy controls (P < 0.0001). MBL levels were variable in different clinical categories of SLE. Lower levels were associated with musculoskeletal and cutaneous manifestations (P = 0.002), while higher and intermediate MBL levels were significantly associated with nephritis in combination with other systemic manifestations (P = 0.01 and P = 0.04 respectively). Plasma MBL correlated with systemic lupus erythematosus disease activity index (SLEDAI) (P = 0.0003, r = 0.36), anti-dsDNA (P < 0.0001, r = 0.54), proteinuria (P < 0.0001, r = 0.42) and negatively correlated with C3 (P = 0.007, r = -0.27) and C4 (P = 0.01, r = -0.29).

Conclusions

Plasma MBL is a promising marker in the assessment of SLE disease activity.
Appendix
Available only for authorised users
Literature
1.
Danchenko N, Satia JA, Anthony MS: Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006, 15: 308-318. 10.1191/0961203306lu2305xx.CrossRefPubMed
2.
Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y, Abu-Shakra M, Barzilai O, Berkun Y, Blank M, de Carvalho JF, Doria A, Gilburd B, Katz U, Krause I, Langevitz P, Orbach H, Pordeus V, Ram M, Toubi E, Sherer Y: The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases-2008. Isr Med Assoc J. 2008, 10: 8-12.PubMed
3.
Malaviya AN, Singh RR, Singh YN, Kapoor SK, Kumar A: Prevalence of systemic lupus erythematosus in India. Lupus. 1993, 2: 115-118. 10.1177/096120339300200209.CrossRefPubMed
4.
Chandrasekaran AN, Radhakrishna B: Rheumatoid arthritis and connective tissue disorders: India and South-East Asia. Baillieres Clin Rheumatol. 1995, 9: 45-57. 10.1016/S0950-3579(05)80142-6.CrossRefPubMed
5.
Malaviya AN, Chandrasekaran AN, Kumar A, Shamar PN: Systemic lupus erythematosus in India. Lupus. 1997, 6: 690-700. 10.1177/096120339700600903.CrossRefPubMed
6.
Kumar A: Indian guidelines on management of SLE. J Indian Rheumatol Assoc. 2002, 10: 80-96.
7.
Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D: Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum. 1996, 39: 370-378. 10.1002/art.1780390304.CrossRefPubMed
8.
Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE: Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies?. J Rheumatol. 1996, 23: 1891-1896.PubMed
9.
Pisetsky DS: The role of innate immunity in the induction of autoimmunity. Autoimmun Rev. 2008, 8: 69-72. 10.1016/j.autrev.2008.07.028.CrossRefPubMed
10.
Pradhan V, Surve P, Ghosh K: Mannose binding lectin (MBL) in autoimmunity and its role in systemic lupus erythematosus (SLE). J Assoc Physicians India. 2010, 58: 688-690.PubMed
11.
Medzhitov R: Origin and physiological roles of inflammation. Nature. 2008, 454: 428-435. 10.1038/nature07201.CrossRefPubMed
12.
Super M, Thiel S, Lu J, Levinsky RJ, Turner MW: Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet. 1989, 2: 1236-1239.CrossRefPubMed
13.
Tegla CA, Cudrici C, Patel S, Trippe R, Rus V, Niculescu F, Rus H: Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. 2011, 51: 45-60. 10.1007/s12026-011-8239-5.PubMedCentralCrossRefPubMed
14.
Tsai YC, Yeh KW, Yao TC, Huang YL, Kuo ML, Huang JL: Mannose-binding lectin expression genotype in pediatric-onset systemic lupus erythematosus: associations with susceptibility to renal disease and protection against infections. J Rheumatol. 2011, 38: 1429-1435. 10.3899/jrheum.100961.CrossRefPubMed
15.
Seelen MA, Trouw LA, van der Hoorn JW, Fallaux-van den Houten FC, Huizinga TW, Daha MR, Roos A: Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin Exp Immunol. 2003, 134: 335-343. 10.1046/j.1365-2249.2003.02274.x.PubMedCentralCrossRefPubMed
16.
Zimmermann-Nielsen E, Baatrup G, Thorlacius-Ussing O, Agnholt J, Svehag SE: Complement activation mediated by mannan-binding lectin in plasma from healthy individuals and from patients with SLE, Crohn's disease and colorectal cancer. Suppressed activation by SLE plasma. Scand J Immunol. 2002, 55: 105-110. 10.1046/j.1365-3083.2002.01035.x.CrossRefPubMed
17.
Stuart LM, Takahashi K, Shi L, Savill J, Ezekowitz RA: Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. J Immunol. 2005, 174: 3220-3226.CrossRefPubMed
18.
Bouwman LH, Roep BO, Roos A: Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol. 2006, 67: 247-256. 10.1016/j.humimm.2006.02.030.CrossRefPubMed
19.
Sandrin-Garcia P, Brandao LA, Coelho AV, Guimaraes RL, Pancoto JA, Segat L, Donadi EA, de Lima-Filho JL, Crovella S: Mannose binding lectin gene (MBL2) functional polymorphisms are associated with systemic lupus erythematosus in southern Brazilians. Hum Immunol. 2011, 72: 516-521. 10.1016/j.humimm.2011.03.007.CrossRefPubMed
20.
Villarreal J, Crosdale D, Ollier W, Hajeer A, Thomson W, Ordi J, Balada E, Villardell M, Teh LS, Poulton K: Mannose binding lectin and FcgammaRIIa (CD32) polymorphism in Spanish systemic lupus erythematosus patients. Rheumatology (Oxford). 2001, 40: 1009-1012. 10.1093/rheumatology/40.9.1009.CrossRef
21.
Piao W, Liu CC, Kao AH, Manzi S, Vogt MT, Ruffing MJ, Ahearn JM: Mannose-binding lectin is a disease-modifying factor in North American patients with systemic lupus erythematosus. J Rheumatol. 2007, 34: 1506-1513.PubMed
22.
Jakab L, Laki J, Sallai K, Temesszentandrasi G, Pozsonyi T, Kalabay L, Varga L, Gombos T, Blasko B, Biro A, Madsen HO, Radics J, Gergely P, Fust G, Czirjak L, Garred P, Fekete B: Association between early onset and organ manifestations of systemic lupus erythematosus (SLE) and a down-regulating promoter polymorphism in the MBL2 gene. Clin Immunol. 2007, 125: 230-236. 10.1016/j.clim.2007.08.020.CrossRefPubMed
23.
Ip WK, Chan SY, Lau CS, Lau YL: Association of systemic lupus erythematosus with promoter polymorphisms of the mannose-binding lectin gene. Arthritis Rheum. 1998, 41: 1663-1668.PubMed
24.
Panda AK, Parida JR, Tripathy R, Pattanaik SS, Ravindran B, Das BK: Low producer MBL genotypes are associated with susceptibility to systemic lupus erythematosus in Odisha, India. Hum Immunol. 2012
25.
Takahashi R, Tsutsumi A, Ohtani K, Muraki Y, Goto D, Matsumoto I, Wakamiya N, Sumida T: Association of mannose binding lectin (MBL) gene polymorphism and serum MBL concentration with characteristics and progression of systemic lupus erythematosus. Ann Rheum Dis. 2005, 64: 311-314. 10.1136/ard.2003.020172.PubMedCentralCrossRefPubMed
26.
Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1725-CrossRefPubMed
27.
Nasiri S, Karimifar M, Bonakdar ZS, Salesi M: Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic. Rheumatol Int. 2010, 30: 1605-1609. 10.1007/s00296-009-1201-3.CrossRefPubMed
28.
Narayanan K, Marwaha V, Shanmuganandan K, Shankar S: Correlation between systemic lupus erythematosus disease activity index, C3, C4 and anti-dsDNA antibodies. Medical Journal Armed Forces India. 2010, 66: 102-107. 10.1016/S0377-1237(10)80118-2.CrossRef
29.
Glesse N, Monticielo OA, Mattevi VS, Brenol JC, Xavier RM, da Silva GK, Dos Santos BP, Rucatti GG, Chies JA: Association of mannose-binding lectin 2 gene polymorphic variants with susceptibility and clinical progression in systemic lupus erythematosus. Clin Exp Rheumatol. 2011, 29: 983-990.PubMed
30.
Lee YH, Witte T, Momot T, Schmidt RE, Kaufman KM, Harley JB, Sestak AL: The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis. Arthritis Rheum. 2005, 52: 3966-3974. 10.1002/art.21484.CrossRefPubMed
31.
Garred P, Larsen F, Madsen HO, Koch C: Mannose-binding lectin deficiency--revisited. Mol Immunol. 2003, 40: 73-84. 10.1016/S0161-5890(03)00104-4.CrossRefPubMed
32.
Tsutsumi A, Sasaki K, Wakamiya N, Ichikawa K, Atsumi T, Ohtani K, Suzuki Y, Koike T, Sumida T: Mannose-binding lectin gene: polymorphisms in Japanese patients with systemic lupus erythematosus, rheumatoid arthritis and Sjogren's syndrome. Genes Immun. 2001, 2: 99-104. 10.1038/sj.gene.6363744.CrossRefPubMed
33.
Thiel S, Holmskov U, Hviid L, Laursen SB, Jensenius JC: The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin Exp Immunol. 1992, 90: 31-35.PubMedCentralCrossRefPubMed
34.
Huang YF, Wang W, Han JY, Wu XW, Zhang ST, Liu CJ, Hu QG, Xiong P, Hamvas RM, Wood N, Gong FL, Bittles AH: Increased frequency of the mannose-binding lectin LX haplotype in Chinese systemic lupus erythematosus patients. Eur J Immunogenet. 2003, 30: 121-124. 10.1046/j.1365-2370.2003.00370.x.CrossRefPubMed
35.
Monticielo OA, Mucenic T, Xavier RM, Brenol JC, Chies JA: The role of mannose-binding lectin in systemic lupus erythematosus. Clin Rheumatol. 2008, 27: 413-419. 10.1007/s10067-008-0838-8.CrossRefPubMed
36.
Sullivan KE, Wooten C, Goldman D, Petri M: Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum. 1996, 39: 2046-2051. 10.1002/art.1780391214.CrossRefPubMed
37.
Illei GG, Tackey E, Lapteva L, Lipsky PE: Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 2004, 50: 2048-2065. 10.1002/art.20345.CrossRefPubMed
38.
Aggarwal R, Sequeira W, Kokebie R, Mikolaitis RA, Fogg L, Finnegan A, Plaas A, Block JA, Jolly M: Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res (Hoboken). 2011, 63: 891-898. 10.1002/acr.20446.CrossRef
39.
Ekman C, Jonsen A, Sturfelt G, Bengtsson AA, Dahlback B: Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2011, 50: 1064-1069. 10.1093/rheumatology/keq459.CrossRef
40.
Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M: High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther. 2011, 13: R71-10.1186/ar3332.PubMedCentralCrossRefPubMed
41.
Pizarro S, Monarrez Espino J, Ruiz A, Jara LJ, Nava A, Riebeling-Navarro C: Soluble vascular cell adhesion molecule-1 indicates SLE disease activity and specific organ involvement. Rev Alerg Mex. 2007, 54: 189-195.PubMed
42.
Davies KA, Schifferli JA, Walport MJ: Complement deficiency and immune complex disease. Springer Semin Immunopathol. 1994, 15: 397-416. 10.1007/BF01837367.CrossRefPubMed
43.
Botto M, Walport MJ: C1q, autoimmunity and apoptosis. Immunobiology. 2002, 205: 395-406. 10.1078/0171-2985-00141.CrossRefPubMed
44.
Ho A, Barr SG, Magder LS, Petri M: A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2001, 44: 2350-2357. 10.1002/1529-0131(200110)44:10<2350::AID-ART398>3.0.CO;2-A.CrossRefPubMed
45.
Ho A, Magder LS, Barr SG, Petri M: Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 2001, 44: 2342-2349. 10.1002/1529-0131(200110)44:10<2342::AID-ART397>3.0.CO;2-8.CrossRefPubMed
46.
Bagavant H, Fu SM: Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol. 2009, 21: 489-494. 10.1097/BOR.0b013e32832efff1.PubMedCentralCrossRefPubMed
47.
Avihingsanon Y, Hirankarn N: Major lupus organ involvement: severe lupus nephritis. Lupus. 2010, 19: 1391-1398. 10.1177/0961203310376522.CrossRefPubMed
48.
Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M: Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant. 1998, 13: 1984-1990. 10.1093/ndt/13.8.1984.CrossRefPubMed
49.
Banda NK, Wood AK, Takahashi K, Levitt B, Rudd PM, Royle L, Abrahams JL, Stahl GL, Holers VM, Arend WP: Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum. 2008, 58: 3081-3089. 10.1002/art.23865.PubMedCentralCrossRefPubMed
50.
Tomana M, Schrohenloher RE, Reveille JD, Arnett FC, Koopman WJ: Abnormal galactosylation of serum IgG in patients with systemic lupus erythematosus and members of families with high frequency of autoimmune diseases. Rheumatol Int. 1992, 12: 191-194. 10.1007/BF00302151.CrossRefPubMed
Metadata
Title
Mannose binding lectin: a biomarker of systemic lupus erythematosus disease activity
Authors
Aditya K Panda
Jyoti R Parida
Rina Tripathy
Sarit S Pattanaik
Balachandran Ravindran
Bidyut K Das
Publication date
01-10-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4057

Other articles of this Issue 5/2012

Arthritis Research & Therapy 5/2012 Go to the issue

Research article

Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation

Research article

Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment

Letter

Response to 'Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4'

Review

New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis

Research article

Th17 expansion in granulomatosis with polyangiitis (Wegener's): the role of disease activity, immune regulation and therapy

Research article

Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits